This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Mood disorders
  • /
  • Benefit-Risk Assessment of Esketamine Nasal Spray ...
Journal

Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression

Read time: 1 mins
Published:1st Feb 2021
Author: Katz EG, Hough D, Doherty T, Lane R, Singh J, Levitan B.
Availability: Free full text
Ref.:Clin Pharmacol Ther. 2021 Feb;109(2):536-546.
DOI:10.1002/cpt.2024
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest